Sign in

Research summary ·

Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This review compared a blood marker, plasma neurofilament light chain (NfL), with other Alzheimer's markers. Others were Aβ42, Aβ40 and p-tau217, plus the Aβ42/Aβ40 ratio. It looked at people with normal thinking, mild cognitive impairment and Alzheimer's disease. Treatments work well in early stages, so reliable blood tests are needed.

What they found

Plasma NfL and p-tau217 rose across disease stages. Aβ42 and the Aβ42/Aβ40 ratio were lower in both patient groups than in controls. Aβ40 was similar across groups. Plasma NfL tracked nerve injury and disease severity. This held from the earliest clinical stage. Results varied across the studies.

What it means for patients

The team says NfL may be most useful together with p-tau217 and Aβ tests. Together they could give a fuller blood-based picture of Alzheimer's changes and nerve injury.

Why it is not certain yet

Results varied across studies. The team says more studies are needed. They must confirm prognostic use and set cut-off values for clinical use. A review can only be as good as the studies in it.

Source

Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

PubMed · PMID 42883821

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Alzheimer disease publications